In this episode, we discuss the diagnosis and management/monitoring of Clonal Cytopenias of Unknown Significance (CCUS) with Dr. Uma Borate. We also discuss the emerging data on risk stratification and key trials in this space that are currently ongoing. Here are the shownotes:

1. CCUS and risk of transformation to myeloid neoplasms:
https://www.sciencedirect.com/science/article/pii/S0006497121013471

2. Prediction of risk for myeloid neoplasms in clonal hematopoiesis:

https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200310

3. CHRS risk score:

http://www.chrsapp.com

4. Germline predisposition to clonal hematopoiesis: 

https://www.sciencedirect.com/science/article/abs/pii/S0145212623006094?via%3Dihub

https://www.nature.com/articles/s41586-020-2819-2

5. Cancer therapy shapes the fitness landscape of clonal hematopoiesis:

https://www.nature.com/articles/s41588-020-00710-0

6. Canakinumab for the prevention of progression to cancer in patients with Clonal Cytopenias of Unknown Significance, IMPACT Study:

https://clinicaltrials.gov/study/NCT05641831?cond=CCUS%20Clonal%20Cytopenia%20of%20Undetermined%20Significance&rank=3

7. Ivosidenib in patients with CCUS and mutations in IDH1:

https://classic.clinicaltrials.gov/ct2/show/NCT05030441

https://sites.wustl.edu/pimm/